reason report
data analyt integr initi mp pt
bottom line initi coverag health servic inc
market perform rate price target
posit overal cro industri number clinic trial
compani drug develop continu increas
bio-tech fund seem robust us believ
expertis oncolog therapeut categori
growth come also like
acquisit symphoni health market
oper grow rate stock market perform sever
reason first top-lin growth rate slow recent
net book growth also slow worri backlog
burn-off rate also deterior slightli manag talk
delay trial start aggress focu pharma
 budget given rhetor washington revenu
guidanc call re-acceler growth worri
expect may high convinc
symphoni deal lead signific share-gain initi
coverag market perform rate pt
cro sector grow busi model high-valu
gener posit contract research organ cro
market total number compani activ pipelin total
drug develop pharma spend rise
along number annual fda approv base find
parexel bio-pharmaceut sourcebook
see number world-wide activ project develop
increas level clinic develop pre-clin
phase sinc number drug pre-clin develop
increas compound-annual-growth-rate phase i-iii increas
compound-annual-growth-rate isr industri standard research
estim phase iv spend outsourc
expect increas clinic pipelin
all-tim high pharma percent sale
increas pharma margin stronger healthcar sub-
sector improv time site identif site select
seem focus right area mainli
focus oncolog immunolog central nervou system inflamm
respiratori cardio-metabol infecti diseas accord
inform evalu pharma mani area see
highest spend oncolog spend well ahead
second place spend like focus
area garner attent though
believ fairli common throughout cro industri
methodolog average ep
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm non-gaap ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
need invest even data analyt softwar
solut acquir symphoni health view
cro industri move toward data-driven model
analyt use virtual remot trial site patient
select well patient monitor regulatori report
like idea symphoni deal estim
use symphoni year seem clinic
trial data busi run side-by-sid without sort
major invest technolog creat newli integr
solut modul sponsor client data solut
revenu actual declin y/i behind expect growth
overal busi also seem slow believ
complet earn-out payment process symphoni
leadership chang process bulk
sale forc data solut divis believ
op well ahead regard breadth depth
data avail sponsor client also believ built
highli differenti softwar solut expedit clinic trial
commerci process view need invest even
heavili data softwar solut effect use data
order remain competit longer term
recent slow revenu growth concern past
quarter beaten adjust ep estim time
adjust ebitda time revenu estim
time firm track-record good concern
past quarter actual miss consensu revenu
expect data solut come behind manag plan
deliv y/i revenu growth constant currenc
well behind y/i growth experienc first
quarter manag talk slowdown trial start
greater attent paid budget pharma
medicar rhetor come washington late
slight uptick cancel later fill replac
project indic hire fte order work
back-fil order revenu growth guidanc call
growth constant currenc worri revenu growth
expect might risk given slowdown growth rate net
new busi award backlog convers view may
take share given firm vast data resourc
look attract entri point initi coverag
market perform rate pt like
cro space believ good capabl believ
like take share possibl bundl togeth solut
might provid lower over-al price-point sponsor
ep estim slightli behind consensu suspect
expect high
initi coverag inc market perform rate
price target life-sci focus contract research organ two main
report segment clinic research data solut compani act partner
biotechnolog pharmaceut compani look run clinic trial effici time
cost sensit manner life scienc industri grow drug
approv product develop ever fund remain high
pharma margin remain strong like overal cro industri recent acquir
symphoni health provid data applic analyt consult servic life
scienc industri effort maintain posit increasingli competit industri
like acquisit expand offer though believ ia op legaci
im data offer former quintil cro remain best posit industri
prah stock rel volatil past year fluctuat
multipl occas believ approach fair valu time
result rate share market perform price target
global contract research organ cro
provid clinic develop outsourc data servic biotechnolog
pharmaceut industri mainli focus major therapeut area includ oncolog
immunolog central nervou system inflamm respiratori cardio-metabol infecti
diseas global level compani invest medic informat clinic
technolog overal goal improv studi predict offer better transpar
throughout clinic develop process data solut standpoint compani
serv custom across entir product life-cycle improv trial design recruit
execut creat real-world data solut increas effici biotech
pharmaceut compani commerci organ global offic north
america europ asia latin america south africa australia middl east
employe particip world-wide clinic trial sinc
led fda intern regulatori approv drug perform
servic biotechnolog pharmaceut compani past year
compani expect strateg solut offer continu build pre-exist
relationship larg pharma compani also establish global partner
choic small- mid-siz pharma compani
background compani offer
cro industri grown significantli sinc sinc
expand offer limit clinic trial servic full servic industri broad client
relationship encompass entir drug develop process servic today includ protocol
design manag monitor phase phase iv clinic trial data
manag lab test medic safeti review statist analysi among other
servic gener time high qualiti data analysi support regulatori
approv new drug reformul exist market claim focu
experi effici captur manag analyz larg stream data come
clinic trial produc standard analysi drive quicker overal develop process
approv given natur end-market abl establish long-term
relationship custom success trial like drive futur busi opportun
addit trial product well new product custom may
pipelin clinic trial phase last multipl year believ offer greater
opportun error custom perspect work cro
trial effici data accur result action determin
whether product advanc
cover wide rang servic
offer segment two report categori rel broad
reach compani two segment clinic research data solut first cover
broad array servic across entir clinic develop spectrum latter provid
data analyt technolog consult solut life scienc market combin
two offer complement valu compani add custom
servic offer includ product registr strateg solut earli
develop servic product registr includ phase iib phase product
registr phase iv trial includ post market commit registri strateg
solut gear toward provid embed solut outsourc servic
custom prah team fulli integr within client intern clinic develop
oper respons manag function across entir drug develop
pipelin final earli develop servic includ phase phase iia clinic trial
bioanalyt laboratori servic total prah offer cover entireti clinic
develop process complet set outsourc servic offer custom abil
let run entir process
global cro platform market leader prah cro one largest world
offic locat throughout north america europ asia latin america south africa
australia middl east team dedic seamlessli execut clinic trial
throughout world time compani highlight presenc scale
differenti market biopharmaceut compani increasingli search greater
patient access among complex trial regulatori constraint abl sourc
global carri trial adher vari jurisdict simultan
broad flexibl servic offer believ complet offer place
among select group capabl provid tradit project-cent cro
servic well embed function outsourc servic provid allow
compani meet need custom rang small biotechnolog compani
larg pharma compani develop clinic trial expertis experi
year span clinic trial phase product registr offer
offer project-bas cro servic built reput partner choic mani
biotech pharma compani strateg solut offer
target larg pharma compani look maintain greater control process
suit need broad market
expertis larg area drug develop therapeut expertis
mani largest area clinic develop area includ oncolog immunolog
central nervou system inflamm infecti diseas particip
clinic trial sinc area alon gain valuabl knowledg
expertis futur trial lead author area abl prepar develop plan
establish studi protocol design identifi site patient submit regulatori file
streamlin fashion benefit custom
approach clinic trial medic informat look remain industri leader
come develop global scalabl sustain solut client
compani look drive improv system process continu invest
medic informat technolog analyt infrastructur deliveri system allow
rapid web-bas deliveri trial data client team compani view analysi
applic data key differenti allow identifi product site
speed enrol drive overal develop timelin compani invest
medic informat larg databas aggreg patient medic data order better
understand patient within unit state acquir data sourc offer
compani signific amount inform patient popul enhanc
enrol process includ medic claim data hospit charge-mast data pharmaci
data laboratori data payer data invest on-going develop
industri toward data-centr model believ well posit grow
current medic informat site includ physician hospit pharmaci databas
cover million patient live billion patient pharmaci claim us
symphoni health look becom leader integr health data
analyt acquisit support compani drive enhanc futur clinic
develop method increas popular best-in-class technolog
solut abl deliv deep data-driven insight creat optim global clinic
studi process drug commerci
year servic accumul diversifi attract client
base perform servic biotechnolog pharmaceut
compani recent expand relationship larg pharma recent year
expand custom base allow pursu strateg allianc global level
broad therapeut expertis flexibl clinic develop servic offer
depend small number custom revenu come
top ten custom rel reliant small base addit largest
singl studi account total revenu compani appear
rel divers grow custom base revenu share smaller custom
offer signific diversif believ compani like grow futur
depend small number compani may put pressur stock especi
neg news
recent sold high low gener stock
rel volatil sinc past year share rel rang bound
multipl fluctuat includ fall low rang
gener market sell-off decemb sell-off concern
lead us believ volatil believ late cycl market could provid
addit downsid plu side howev current trade around
midpoint rang impli upsid previou resist
symphoni may transform investor seem believ symphoni
offer custom sort transform clinic trial experi similar op
seem belief signific cross-sel synergi forward
year like symphoni asset view use data
decad doesnt seem aggress plan place creat new softwar
solut acceler rapidli transform way clinic trial done
past
busi growth may slow like firm overal industri
worri compani overal growth rate slow net new book growth
y/i net new book growth increas y/i compar
y/i growth y/i growth furthermor backlog burn-rat
slow net book-to-bil declin worri get aggress
price prah data asset may competit im
expect seem high manag guid y/i top-lin growth
constant currenc view may high given prah top-lin grew
constant currenc past manag highlight delay trial start
cancel refil comment around pharma becom
budget consciou due rhetor around medicar view
particular highlight item caus us worri company-specif
slowdown histor manag met exceed investor expect miss
could potenti lead sharp sell-off
margin growth somewhat volatil manag recent hire net new peopl
order accommod new busi win view adjust ebitda margin
gross margin expans somewhat errat like manag seem
focus control manag cost volatil firm
biotech fund environ key entir cro industri depend heavili
biotech pharma fund environ check indic fund remain
robust number clinic trial process continu rise howev also believ
market becom competit uptick delay trial cancel could
caus stock sell
grow complex end-market offer strong demand
manag highlight two key trend growth driver market move forward
 spend outsourc penetr expect rise
manag refer industri standard research isr highlight
market trend compani highlight estim cro market
expect grow compound-annual-growth-rate furthermor isr highlight
biopharma spend expect grow annual spent
develop includ phase phase iv clinic develop
manag expect continu growth area biopharmaceut compani begin
look addit revenu stream number high profil drug come patent
come year creat revenu void compani creat increas
demand new drug approv healthi capital-rais environ turn result
growth opportun cro industri manag also suggest fund
biotechnolog compani receiv primarili use fund clinic trial
often use given lack exist infrastructur compani
isr estim phase iv spend outsourc
furthermor number expect grow given expect growth
total spend percent spend expect go see strong case
cro perform next year reason expect increas
util includ need maxim product reduc cost increas complex
trial simultan multi-countri registr increas cost declin
product industri becom valuabl given expertis compar
pharmaceut compani may abl experi in-hous addit burden
complex grown significantli regulatori requir world-wide requir data
analysi approv standard requir constantli chang
updat cro compani abl benefit experienc team keep up-
to-dat market regul creat effici adher process abl
cover regul multipl countri limit amount addit work need
done regist global
clinic pipelin continu grow
accord pharma intellig seen strong increas total number
compani activ pipelin past year furthermor pharma intellig show
slight shift number compani space headquart locat
standpoint increas china rest apac
unit state europ seen modest declin percent total
figur total number compani activ pipelin increas
figur hq china rest apac increas percent total
like benefit grow pipelin compani drug activ develop
support increas overal spend among end-market furthermor
technolog advanc industri continu innov becom effici
expect compani enter strong vision hefti fund base need cro
help develop process young compani money
spend benefit view believ industri continu grow
new busi well alreadi exist domin pharmaceut biotech
compani look expand portfolio intern develop acquisit
trend continu expect benefit larg custom increas util
new custom pose long-term opportun fund ventur capit global
pharmaceut institut continu grow prah prospect valu
iqvia world largest cro estim new molecular entiti nme
approv compar
suggest continu expans industri given increas spend
need effici healthcar system believ early-stag market continu
increas util offer state-of-the-art product servic well
experienc tenur staff drive best result follow chart see
percentag sale pharma continu grow percentag total sale
increas expect continu increas amount spend
among pharmaceut compani view strong benefit move
figur pharma revenu increas
believ biopharmaceut compani face increasingli difficult environ
improv standard care new type therapi biolog genet target
therapi gene stem cell therapi modal well posit assist
compani manag complex come new highli regul
environ especi earli stage develop process broad set
offer rang product registr late stage servic approv
benefit earli custom penetr life scienc environ becom
complex prah extens grow knowledg base like contribut share gain
opportun grow cro custom success creat futur opportun
road repeat servic larger custom acquir smaller life scienc
compani could also bring product otherwis might access
compani look work wide rang custom multi-national pharmaceut
compani small biopharmaceut compani assist product develop mainli
america though grow global presenc global industri continu grow
see grow number drug pipelin increas densiti compani need
focus way best develop process ensur effici cost effect
although past two year number drug stage remain rel flat
encourag see strong growth number stage compani continu
drive innov well overal uptrend number approv nda
figur number drug stage continu rise
increas complex standard drug develop overal cost
increas dramat studi tuft center studi drug develop
overal out-of-pocket cost new drug develop significantli
last decad increas cost effici import ever
abl make inform decis earli process key success achiev return
invest compani help custom succeed earli develop
process potenti save substanti amount time money given
complex set run clinic trial believ allow custom abil
re-focu fund effort way drive improv overal healthcar
industri via increas probabl success
figur bring drug market
tuft center studi drug develop
pharma margin lead way healthcar industri use data compil
nyu januari see pharma biotech compani well term
gross oper ebtida margin compar sector healthcar space
sell sector rel high margin see posit
figur pharma margin strong
prove valu clinic trial
parexel biopharmaceut statist sourcebook
sourcebook parexel highlight variou trend view favor cro
market first early-stag develop late stage develop
work outsourc primarili led small pharma howev encourag
see larg pharma compani approach util outsourc late
stage discoveri stage total work outsourc time
view potenti opportun move forward
world-wide activ pipelin grow significantli highlight pre-clin drug
support comment parexel suggest strong increas overal
pipelin growth drug phase i-iii clinic trial appear slightli lower
number drug preclin develop grown rather significantli sinc number
drug preclin develop increas compound-annual-growth-rate compar phase
phase ii phase like strong growth number
drug pre-clin develop believ move forward larger percent
begin make way clinic trial phase furthermor believ strong
growth phase trial sign increas effici smarter decis earlier
develop process overal believ number project pipelin continu
figur world-wide pipelin continu grow
drive quicker site cycl time repeat new site compar sponsor
cro proven abl drive quicker overal site cycl time includ total week
site identif site select studi start measur done repeat site
well new site appear much effici process accord
parexel total cycl time repeat site averag week cro compar
week sponsor similarli use new site total cycl time cro averag
week compar week sponsor view differ signific
demand driver clearli abl drive effici process attempt
drive overal develop process timelin
activ project developmentpreclinicalphas scienc inc
figur cro drive signific valu cycl time compar sponsor
excel databas build phase ii clinic trial also show valu
come build studi databas phase ii clinic trial averag build
time day well ahead averag other includ sponsor
figur cro excel quickli build releas studi databas ph ii/iii
invest highlight growth driver
focu area expect growth
accord recent public evalu pharma prah focu area expect
see strong growth rel overal market report suggest overal expect
compound-annual-growth-rate strong growth sale orphan drug
proport sale oncolog drug potenti risk expect
howev includ sale risk drug come patent rel
expens clinic cost cardiovascular drug anticip declin spend
proport prescript sale declin proport prescript sale
concern believ overal net increas amount spend given
expect growth sale
figur world-wide prescript sale expect grow
figur acceler growth achiev compound-annual-growth-rate
prah focu area see growth given focu oncolog immunolog central nervou
system inflamm respiratori cardio-metabol infecti diseas well
inform evalu pharma report encourag prah prospect move
forward evalu pharma suggest oncolog remain main focu biopharma
industri one expens faster grow area believ focu
expertis cro like benefici follow oncolog area
musculoskelet cardiovascular immunomodulatori respiratori
alreadi well penetr fastest grow area believ help drive
futur growth field expand
figur oncolog highest clinic develop spend
use market posit expand relationship biotech small- mid-siz
pharmaceut compani believ strateg partner choic area
compani reli full servic deliv support clinic develop
regulatori process given small compani typic lack expertis carri task
quick effici manner believ like experi
growth compani enter market activ pipelin ventur fund
believ look partner compani succeed given
establish custom base compani believ abl capit grow
opportun see strong area focu given rel concentr prah
revenu top ten custom expand custom base diversifi revenu stream
compani also pathway futur revenu opportun
use multi-n expertis drive valu larg pharma invest
global scale infrastructur past year enhanc statu servic provid
larg pharmaceut compani oper global scale acquisit
rp compani increas depth larg pharma relationship intend
continu expand relationship beyond embed solut provid
strateg solut offer
though well establish among mani top therapeut area look
expand expertis compani establish base therapeut area expect
continu refin busi develop initi link organ key clinic
opinion leader medic informat leverag look expand expertis
exist area oncolog infecti diseas inflamm alreadi
repres major portion drug develop time compani expect growth
target oncolog companion diagnost person medicin area expect
see increas demand dementia alzheim research given age
demograph popul believ continu focu area expertis good
strategi sector continu repres major develop spend time
like commentari regard continu interest area compani see
attract futur
continu enhanc technolog enabl cro model acquisit
symphoni health access rich data insight allow custom clinic
studi har power technolog asset custom allow
studi uniqu patient move forward expect integr
symphoni strong valu proposit look compet bigger
scale largest global
look benefit recent futur acquisit compani expect continu
realiz benefit acquisit complet past five year believ result
addit revenu growth margin improv acquisit complet
complementari compani custom base offer cross-sel opportun
previous avail overal expand scope believ
penetr end-market begin realiz addit synergi previou
acquisit look expand sinc acquir compani
time establish program help compani identifi addit opportun expect
momentum continu futur appropri opportun present
expect near- medium-term focu revolv around data scienc cloud comput
broad set offer
report two segment clinic research data solut clinic research focus
wide array servic across clinic develop spectrum data solut
provid data analyt technolog consult solut life scienc market prah
core servic offer includ product registr strateg solut earli develop
prah product registr area includ design manag implement studi
protocol phase ii phase clinic trial seen build block product
develop program along phase iv post approv clinic trial use
extens resourc expertis design conduct studi global develop
integr global databas collect analyz data receiv trial prepar
regulatori submiss us europ jurisdict world-wide
full-scal program would includ follow area
clinic program develop review consult life-cycle manag plan
clinic protocol design electron crf case report form
patient recruit retent
investig site analysi
investig handbook meet
investig site support clinic monitor
patient medic safeti manag
analysi report
datecompanypric platform patient enrol engag applic analyt consult drive insight pharma base softwar solut clinic research trial manag applic lifetreenaresearch organ focus earli stage patient popul provid clinic develop servic pharma biotech industriesh acquisit historysourc crunchbas compani websit scienc inc
medic scientif public
prepar regulatori file
full suit product registr servic offer highlight
figur offer span earli late stage develop
clinic trial manag biotechnolog pharmaceut client use
exclus collabor custom intern staff clinic trial
servic prah broad clinic trial manag capabl util singl multi-
site set intern set throughout world electron trial
master file etmf abl creat collect store edit retriev electron document
offic locat world-wide abil enabl global project team work
collabor effici manner seamless transfer work effici local
matter locat
figur use data number sourc drive protocol design
project manag project manag manag actual develop process
set specif target use variou metric project manag team
ensur project move right speed right path use resourc effici
team meet client standard studi handl project manag
group overse implement work breakdown structur commun plan
establish risk conting plan project assign project deliveri director
consid key account gener partner assign
project director project manag match project manag personnel
base experi studi specif paramet
regulatori affair regulatori affair team extens experi work
biotechnolog pharmaceut compani well regulatori author global
group intern network local specialist nativ speaker countri across
major market includ north america latin america eastern europ africa
apac specialist act client repres submiss direct
regulatori commun region oper manag believ
expertis allow rapid studi start-up facilit competit product develop plan
effect submiss strategi trial move along
therapeut expertis prah therapeut specialist offer servic scientif
medic expertis patient access retent servic across broad rang therapeut
area global level experi broad reach abl offer complet
global servic solut custom divers therapeut expertis group leverag best-
in-class data asset assist custom clinic develop program design
implement becom increasingli search featur accord
manag therapeut expertis offer design implement stage
lead high-qual develop program help custom achiev key mileston cost
effect manner servic util emerg biotechnolog compani lack
clinic develop infrastructur requir hous well pharmaceut
compani limit intern medic resourc explor new therapeut
figur divers base specialist
clinic oper highli experienc team clinic research associ
specialist prah clinic oper group oper countri world-wide provid
custom full set study-sit manag monitor servic area experi
includ local regul medic practic safeti individu therapeut area custom
offer fulli train local base clinic team led experienc team manag
initi start-up monitor data review servic base locat global america
europ apac africa work form strateg foundat combin relianc
proven consist process abil adapt innov idea technolog studi
start unit within clinic oper manag key compon rapid site activ
investig site set trial use global region-specif expertis
data program servic offer innov suit technolog gather
organ clinic trial data global data program servic group
employ industri lead electron data captur edc technolog innov deliveri
system gener high qualiti standard data report compani focus
evalu custom need order present optim solut trial follow
effici solut implement project execut group technolog specialist
drug research form support goal drive strong foundat data
manag core program abil
safeti risk manag dedic safeti risk manag group
assist client design implement operation proper safeti procedur
develop post market offer allow clear assess
commun patient safeti protocol lead increas regulatori adher global
safeti risk manag center stage experienc drug safeti associ
respons integr effect risk minim strategi drug product
gener usabl inform on-going evalu offer also includ risk
mitig strategi custom stage drug develop cycl well
figur safeti main area focu
biostatist medic write biostatist medic write oper unit work
integr prah biostatist medic write pharmacokinet regulatori publish
group staff experienc therapeut train biostatistician medic
writer offer client expertis statist analysi data pool regulatori report
first stage protocol design post market surveil phase iv studi
biostatist medic write team support consult expertis across world
unit use special electron system enabl team assembl manag
publish complex document compli local regulatori requir
qualiti assur servic prah qualiti assur team experienc profession
america europ apac separ team personnel engag
direct conduct clinic trial group object global promot on-going
qualiti awar continu process improv group perform audit
process system use clinic trial manag order ensur complianc
studi protocol local regulatori requir phase global
late-phas servic late phase servic group support global region post
approv trial central locat manag pennsylvania germani singapor
support late phase servic client post market process group help identifi
trend signal larger popul plan conduct safeti surveil studi larger
biomark research team industri lead strateg specialist oper
specialist epidemiologist late phase servic unit work collabor
custom identifi object goal translat comprehens studi design
post-market research
strateg solut segment offer biotechnolog pharmaceut compani abil
execut intern manag develop portfolio flexibl leverag exist
infrastructur minim repetit offer includ wide spectrum solut allow
effici manag execut critic clinic develop function
pharmaceut custom emb employe custom infrastructur creat
strateg interdepend relationship allow anticip custom clinic trial
demand allow effici deploy clinic profession meet custom
need satisfact requir clinic function support servic includ
product safeti primari solut focu total phase ii phase iv
develop market manag believ offer wide-rang servic compar
tradit project base cro target outsourc compon biopharmaceut
embed solut believ compani industri strateg
clinic oper expertis manag infrastructur support aim creat flexibl
integr oper model model look enabl custom intern manag
develop process execut greater flexibl enhanc
achiev leverag system technolog compani work partner
help redesign pre-exist system process effort drive improv effici
speed qualiti implement innov approach enhanc technolog drive
improv strong govern structur robust metric abl
measur ensur continu strong qualiti cycl time product servic level
function servic provid solut provid dedic capac manag singl
oper platform within one function across multipl function geographi
custom provid direct function manag provid resourc
line manag train support also util metric busi level
ensur relev experienc staff member deploy correctli drive consist
staff augment solut provid custom abil address staf need
access resourc qualifi meet clinic develop need
provid custom abil maintain flexibl also reduc fix cost
assembl believ largest team industri focus personnel
recruit effort attract recruit qualifi employe particular situat
custom offer variou locat offer includ site offic
peopl process system develop expertis enabl effici intern develop
compani product portfolio control flexibl acceler timelin reduc
cost client core leadership remain control help build develop
team meet client need enabl client keep flexibl life-cycle
commerci servic commerci servic offer assist custom
address post approv commerci challeng compani deploy profession
knowledg prepar launch product life-cycle manag assist
product life-cycle manag work creat concis messag engag thought
leadership healthcar provid gener consum interest prepar post
market commit effect round compani offer throughout
product develop life-cycle allow involv custom major
process commerci servic deliv embed solut
servic provid model staff augment
prah earli develop servic ed offer includ full rang phase
phase iia servic well bioanalyt offer compani conduct studi
major pharmaceut compani europ us japan well mani smaller
emerg biotechnolog custom result built larg base avail subject
includ healthi volunt patient popul split specif medic
ed grown recent year via acquisit expand phase phase ii
servic expans includ offer focus conduct design earli stage
popul therapeut focus human abus liabil addict pain psychiatr
neurolog pediatr infecti diseas servic one
world abil design conduct studi regulatori requir
central nervou system compound posit one largest provid patient
popul phase studi confin phase ii phase servic us
believ abl provid client full rang phase phase clinic research
ed support servic rang protocol develop data manag
pharmaci servic includ manufactur investig medicin product lab
provid pharmacokinet branch pharmacolog concern movement
drug throughout bodi pharmacodynam branch concern effect
mechan drug action safeti laboratori support clinic act
central lab mid-siz phase ii trial
earli develop specialist throughout five clinic pharmacolog
unit four differ countri us netherland central/eastern european locat
last five year conduct high-level complex earli develop
clinic trial bioanalyt studi annual time period
phase i-iia studi offer bed world-wide hous phase studi
accommod volunt clinic pharmacolog unit remain constant
supervis total amass pool studi particip includ
health variou specif patient
use unit-on-demand busi model bring phase center patient model
creat central medic facil special treatment target patient popul
physician recruit high volum patient network refer specialist
gener practition also act investig site phase iib phase trial
also includ compani earli phase offer pharmaci capabl
oper manufactur site design fast flexibl small batch manufactur
investig medicin product need studi
also util ind trial includ microdos low-dos studi pre-screen
candid earli stage order minim number fail clinic product candid
pipelin close involv microdos studi field last ten year
conduct microdos studi
bioanalyt laboratori offer two bioanalyt laboratori one netherland
one kansa lab harmon standard oper procedur work
instruct equip level consist continu effici client
abil run studi either lab depend specif studi requir ensur
receiv level servic lab also oper wide varieti special
assay includ ligand-bind assay multipl detect methodolog
immunogen final laboratori provid full rang analyt throughout
prah data solut segment provid custom data analyt technolog
consult life scienc industri segment purchas data pharmaceut
retail prescrib payer institut user includ patient detail includ
locat purchas drug therapi payer though data remain
anonym individu monthli refresh data allow custom track
analysi therapi purchas longer term
market intellig servic includ target compens prescript
drug sale data servic use compens sale repres pharmaceut
audit suit nation level prescript sale data servic use market research
consult servic includ multipl aspect brand analyt manag
market commerci effect scientif studies/clin hub
brand analyt anonym patient data set servic enabl commerci
analyt includ patient complianc persist switch habit share count
diagnosi patientsourc comprehens patient-level data set offer detail
view patient treatment activ certain diseas categori
manag market suit prescript claims-bas data product analyt tool
leverag claim life-cycle data look understand manag market influenc
commerci effect profession servic unit provid offer enabl
custom optim promot spend activ offer includ digit
promot measur advanc target patient journey market landscap
health econom studi medic affair health econom divis
pharmaceut compani provid real world evid aim support
assess drug clinic effect
technolog includ data servic tech enabl product servic
allow custom analyz symphoni health integr third parti data
list solut
area expertis
acquisit symphoni health close septemb total
symphoni health prah provid data analyt custom compani help
profession understand behavior full market life-cycle rang predict market
analysi patient influenc physician prescrib pharmaci fulfil payer reimburs
sale compens view prah acquisit symphoni way attempt
compet iqvia im data asset
symphoni health offer rang solut includ consult servic market
knowledg app technolog within consult servic symphoni health
consult group provid inform solut expertis assist sale market
profession creat success market strategi market knowledg segment idv
integr datavers establish foundat analyt consult servic
symphoni sourc data major suppli channel includ retail pharmaci wholesal
govern program claim continu work build relationship ensur
continu suppli inform allow improv understand complex healthcar
system involv chang influenc patient payer provid final app
technolog area symphoni recogn need new strategi understand
influenc decis maker biopharmaceut organ need fulli inform
across broad market integr insight key busi process symphoni offer
custom abil util data resourc uncov stakehold valu driver
healthcar industri second total spend world-wide although second
 spend behind comput electron healthcar well ahead
larg industri auto softwar industri chemic believ signific
level spend continu drive growth market compani
well competit believ iqvia best posit industri given strong
data asset howev offer outsourc pharmaceut compani
use vendor industri medidata mp veeva op believ
well posit compet strong solut life scienc tech vendor
in-hous solut among competit end-market success industri
help build reput retain current attract new custom move forward
expect continu build offer base need end-market
expect increas competit given attract spend among end-market custom
seen recent larg tech compani
outsourc shift strateg relationship-bas model accord deloitt
report outsourc relationship focus biolog data-driven innov capac
compani industri capit posit clinic
develop market technolog expertis model becom data
driven cro standpoint compani abl offer manufactur data
resourc might avail sponsor expens in-
hous report suggest one-third develop stage launch
manufactur done hous cro relationship becom crucial
industri growth expect cro util continu increas compani
drug pipelin ever relationship aim reduc
overal cost process gener best possibl commerci success
compani keep process in-hous risk compet
manufactur util expertis view headwind
technolog advanc util key maintain grow cro
posit attent space global level given strong growth spend
level clinic develop market becom competit follow im
quintil merger bought symphoni health bring strong technolog offer
look compet creat addit valu custom compani enter
space includ world largest tech compani need continu
develop applic continu prove use cro custom
believ competit industri benefici long run term new
compet hous univers teach hospit
corp pharmaceut product develop inc syneoshealth major
competit face research develop segment come
also note inher competit individu manufactur vendor may
use solut veeva medidata technolog data center compani
enter space compani contract offer
life scienc compani
ia op form follow merger quintil im health
iqvia cover broad section healthcar landscap primari focu life scienc
servic technolog well clinic research forefront technolog
innov drug develop space given larg presenc extens grow
databas inform iqvia also recent expand presenc commerci
side drug develop process recent announc orchestr custom
engag oce solut solut deal multipl larg pharma
compani believ potenti disruptor industri
covanc contract research organ drug develop compani offer focu
research optim analysi safeti test assess consult partner
clinic develop test commerci manufactur support compani
base unit state found covanc drug develop busi
laboratori corpor america hold labcorp make largest cro world
accord explor biotech link base total labcorp revenu labcorp acquir
covanc creat world lead healthcar diagnost compani
combin clinic laboratori servic end-to-end solut develop
commerci drug diagnost
icon rank explor biotech top ten rank first compani base
unit state list compani base dublin ireland offer custom rang
servic includ consult develop commerci countri
global network icon total nearli revenu total
icon recent acquir molecularmd bolster laboratori offer molecular
diagnost test immunohistochemistri furthermor compani presenc
apac region sinc latin america sinc suggest earli represent
two area expect key growth industri
parexel rank explor biotech top ten list provid support
servic biopharmaceut compani phase i-iv clinic research regulatori consult
market access parexel acquir june approxim pamplona
capit manag prior acquisit parexel revenu growth flatten
rang parexel solut span entir clinic trial
process differ applic stage allow custom process trial
applic intend size scope abl harmon process
protocol acceler time market minim risk last phase failur parexel cloud
base edc provid custom quick effici deploy total flexibl
applic focus resourc need defin sophist sourc data
rank explor biotech top ten list global cro provid
custom drug develop laboratori life-cycle manag servic offer
monitor regulatori data manag real-world outcom other
employe offic countri partner pharma biotech
medic devic compani well academ govern organ throughout
world compani acquir affili carlyl group hellman friedman
cash transact valu recent recapit includ two
fifth largest cro explor biotech top cro list report includ
much in-depth analysi compani includ brief overview base
north carolina provid clinic research data solut custom outsourc
servic avail pharmaceut biotechnolog compani global includ
clinic research clinic trial servic data analyt technolog solut real world insight
revenu compani expand offer
anoth competitor cro space syneoshealth largest cro accord explor
syneo formerli inventiv research inc research also base north carolina
offer integr end-to-end solut focus develop commerci
clinic therapi clinic offer focu develop servic span trial phase
includ global studi differ unbundl servic offer clinic monitor
investig recruit data manag studi start-up commerci standpoint
compani provid servic outsourc field sell solut medic adher
commun consult servic revenu significantli
result acquisit combin inc research inventiv health
figur explor biotech top
figur provid addit inform mention
theme growth via acquisit smaller grow interest util real
world evid drive addit synergi
figur top detail
also see covanc labcorp cro well penetr entir market
provid initi research model usual mice test subject offer servic
extend throughout entir discoveri clinic commerci process like
establish rank list within strike distanc number spot
believ integr symphoni growth driver move forward expand
valu proposit custom follow chart show differ featur solut
servic strongest green shade indic
strength brownish shade show believ cro may
presenc gener compani may case view particularli strong
area
top focuscommentslabcorpnc usaown covanc nonclin clinic commercializationacquir top cro chiltern oncolog org bring cancer patient innov medicin fasterwork top best sell drug avail todayiqvianc usaphas i-iv clinic trial associ lab analyt servicesend-to-end clinic commerci servicelargest cro world organ growth smaller specialist acquisitionsstrong grow rwe presencesyneosnc usaend-to-end solut develop commercializationbiopharmaceut accler model connect clinic commerci bring calu small mid larg size customersparexelma usaconduct clinic trialsexpand lower cost emerg marketspartnership develop china shyft real-world data studiesbought pe firm pamplona bolster profit margin increas qualiti health sciencesnc usaclin research data solut outsourcingacquir kkr brought public control compani specif focu singapor china region sectorsnam best cro asia biopharm asia countriespharmaceut product develop nc usaintegr drug develop lab life-cycle managementacquir evidera real world evidenceacquir synexu patient recruit copmani id patient first deliv sitecharl river labsma usamainli pre-clin focusedlead pre-clin developmentpartn hc center ventur capit firm earli introduct biotechsha research models/servic marketicon public limit corporationdublin irelandconsult develop commerci servicespartnership genom england watsonrec acquir ichom genom england molecularmdacquir mapi group french late stage cro boost rwewuxi apptecshanghai chinar manufactur sm molecul biolog cell/gen therapi devic andmolecular segment cover broad spectrum industri small molecul biolog gene/cel base therapi medic devic genom molecular diagnosticsbas rapidli grow china focu major pace hold incoh usadrug develop medic devicesmids invest intern drive businessintim cohes offic cultur organ growthpotenti acquisit target scienc inc
figur explor biotech top
top clinic trial manag compani solut outsourc partner
oper cloud licens hardwar servic industri cloud
licens market sell deliv applic platform infrastructur
custom hardwar segment includ hardwar product relat softwar oracl
life scienc solut cover clinic data manag develop oper use
help global clinic organ maintain central manag databas offer
user relev inform one main legaci provid product
servic total nearli revenu year end may
come cloud servic licens support name recognit brand
market leader life scienc field capit abil acquir way
medidata histor focus life scienc cloud base solut provid aim
optim develop invest technolog built offer unifi platform
pioneer analyt clinic technolog pharmaceut biotech medic devic
compani fiscal year end decemb revenu medidata smaller
grow compani increas sale around annual past three year
ebit ebitda margin stabil around respect medidata edg
platform offer clinic trial manag system solut edg
cloud nine year program integr medidata solut
provid real time view progress accord medidata websit edg increas
visit report product upward drive oper cost allow
greater focu value-add activ medidata edc applic rave edc allow seamless
random trial suppli medic code safeti report health capabl
work cornerston medidata clinic cloud addit medidata recent
expand commerci side acquisit shyft analyt shyft provid
top modelsdiscoveri serviceschemistrybioanalysistoxicologyimagingphas iphas iiphas iiiphas ivcommerci serviceslabcorp covanc iqviasyneosparexel health sciencespharmaceut product develop charl river labsicon public limit corporationwuxi apptecmedpac hold inc scienc inc
real world data offer medidata entranc commerci process optim
parexel intern corpor
care patient id applic product clinic conductor design
accommod regulatori complianc enhanc clinic research oper type
research organ focus financ recruit particip deliveri result
monitor notif applic also integr edc solut allow
seamless sync abil push info back forth real time one applic
bio-optron announc invest januari mainsail partner
duo goal partner effect scale busi quickli possibl given
avail money intend invest heavili product custom success
grow clinic conductor product number complex clinic trial rise
datatrak develop provis electron clinic solut offer train support
host servic datatrak ctm product modern enterpris trial manag system
offer cloud base saa solut lessen amount time need implement
elimin need expens hardwar applic allow standard import
patient personnel product site vendor deviat directli platform edc
applic offer user complet control easi use interfac support specif
need trial trial basi platform scalabl trial continu grow abl
match protocol datatrak howev lose share revenu declin
year end decemb consist low ebit
veeva provid industri specif cloud base softwar solut life scienc compani
product line cover complet end-to-end process initi file clinic trial
veeva vault field medic market sale veeva vault edc allow
custom run custom trial way best fit need studi deploy
week instead month abil amend fli without downtim veeva revenu
growth declin steadili high one year ipo
recent year-end howev show sign stabil oper margin stabil
around well veeva rather new space method roll
product ensur earli win util client base well note
opportun among life scienc custom satisfi current softwar
lack recent innov
medacorp kol highlight prah posit industri
spoke medacorp kol base europ experi opinion
gener cro industri take away key point discuss
includ sponsor come cro decis prah grow presenc apac
grow opportun cro industri symphoni poor integr far
differ cro decis point includ therapeut specialti geograph locat data
avail kol spoke suggest sponsor often decid cro
variou check point point includ track record cro specif therapeut
area geograph reach abil identifi site reach site investig
avail qualiti data servic offer base comment believ
well posit second tier cro behind iqvia syneo nr covanc
line competitor icon iclr nr parexel cro decis
point also includ prior relationship abil priorit work kol mention one
instanc custom chose cro base previou relationship
execut sponsor base convers appear
competit singl cro combin increas
demand servic believ industri whole well posit growth
work hard develop presenc asia encourag kol
highlight prah grow presenc asia believ loosen regul region
specif china tailwind cro industri kol suggest china offer
tremend market grow significantli offer demand local
intern key challeng access util data region
suggest china lot data abil util data deliv
meaning insight process key growth region believ progress
establish base asia benefici long run expect loosen regul
spur continu innov pharmaceut develop market previous
overal life scienc industri model seem favor kol suggest
signific growth avail cro industri number candid
develop trial continu grow larg pharmaceut compani upward
candid develop suggest larg grow significantli
smaller begin emerg well us mean demand industri
plenti abl spread success particip although like two
leader signific portion industri iqvia covanc breadth depth
life scienc allow healthi competit among cro particip furthermor kol
highlight increas demand earli stage help smaller younger compani
drive forward momentum although suggest strongest phase ii phase iiia
believ increas demand earli stage may offer addit opportun
road would benefici well regard among
small- mid-siz compani
acquir symphoni health reason next step integr appear
lack kol spoke suggest acquisit appropri histor
focus clinic oper compani though integr gone well describ two
distinct busi yet tie togeth mani cro client look full servic
offer rang clinic commerci data requir best outcom
went far suggest may even lose busi lack integr
among two asset iqvia hand success integr quintil cro
im data asset abl build oper around combin offer
take product clinic develop regulatori affair price
concern symphoni integr may go desir custom standpoint
believ focu move forward base size acquisit potenti drive
improv data insight real world analyt well success seen iqvia
anticip symphoni remain focu
spoke ir firm current quiet period lead
earn topic discuss includ compani gross margin trend outlook
slowdown net new busi studi start time well symphoni gener
view data cro industri
gross margin tend fluctuat hire trend chang ir suggest recent new
client industri want see actual peopl would work project
result hire employe prior drive revenu agreement delay
caus fluctuat compani gross margin eventu lead catch
follow studi start furthermor ir suggest distort gm
past year follow transit account
like interest continu grow busi asset base ir
suggest compani interest technolog help improv speed
effici clinic trial wearabl furthermor expect compani
acquir anyth big symphoni near term expect purchas anoth
cro like continu commit grow busi focu end market
believ improv innov technolog continu driver
competit cro industri move forward
slower net new busi growth rate may impact conclus
fast burn studi convers ir highlight certain studi may high
volum quick relat flu studi typic last one flu
season larg number peopl involv rel short time horizon
year less ir suggest conclus one studi like creat
difficult comp believ part reason growth appear slow net
new busi appear lighter expect
use symphoni prior acquisit symphoni client drug
compani addit symphoni histor us compani
believ pose addit opportun futur convers ir suggest
buy data wherev find suggest like
rest industri purchas data legaci im busi believ continu
focu expand symphoni capabl expand databas tailwind
prah busi featur season revenu lumpi call
ir interest hear prah revenu somewhat lumpi due
describ fast burn trial trial like focus flu frequent
wide scope limit durat result sound like deal creat
lumpi tough y/i comp larg chunk revenu book short period
time well discuss season frequent observ prah busi
typic strongest quarter accord ir season larg function drug
compani client spend prah whether flush budget
spend prepar launch plan follow year
slower start time sound result increas complex
tailor approach prah earn call discuss slower start-up time
delay sought clarif ir follow convers believ delay
mention larg result increas complex suggest
improv better serv client discuss sound client typic
put request propos rfp outlin goal potenti anticip trial design
includ respond rfp offer solut meet desir
need also offer altern solut may help improv result client
improv trail design accord convers sound delay typic
occur drug compani alreadi hire result client take
longer anticip decid option trial design would like pursu view
make sens especi given mani drug product develop complex
often aim treat rare diseas sick patient
mr shannon sinc initi serv presid previous
execut vice presid global clinic oper product
develop inc oversaw clinic biostatist data manag
oper global throughout year held multipl posit includ
compani europ divis chief account offic europ
pacif rim prior year experi varieti financi
account posit util multimedia industri
mr bonello name evp cfo may previous serv senior vice
presid account corpor control sinc join prior mr
bonello director finance/corpor control inc vice presid domest
control global report leader
mr thoelk provid corpor oversight strategi scientif medic affair
pharmacovigil patient safeti therapeut center excel world data
patient access experi digit health trial integr
oper deliveri mr thoelk industri pioneer mobil first strategi aim
integr clinic trial provid direct patient access virtual hybrid-virtu trial
model year experi global drug develop diagnost devic
industri experi countri serv co-ceo joint ventur found
wuxi sever year manag clinic drug develop oper china
mr shah join rp incept remain acquisit
previous serv strateg solut assist
develop matur embed sourc model use expertis
includ strateg sourc chang manag optim effect govern
oper structur held posit pharma sector zeneca
pharmaceut well cro sector therorem clinic research parexel
ms klerr came infacar pharmaceut corpor serv vice
presid clinic oper previous spent year varieti senior
busi develop role key account manag oper
david macmurchi execut vice presid europ asia pacif africa
mr macmurchi join octob ernst young ey head
life scienc partner ey led team across servic work extens
japan china europ us work im health variou role
includ vice-president global account initi began career uk experi
leadership strategi disrupt data manag perform improv
harri koffer strateg advisor ceo
mr koffer serv presid strateg solut previous
held sever leadership role rp includ ceo presid acquisit
posit includ vice-president clinic trial pharmaceut busi
develop vice-president gener manag covanc clinic servic
presid covanc periapprov servic year experi clinic
drug develop also serv adjunct assist professor pharmaci
medicin univers pennsylvania school medicin clinic associ professor
pharmaci philadelphia colleg pharmaci scienc
board director
mr barber director nc idea co-manag director fennebresqu co llc
well board six compani work career manag
pricewaterhousecoop llp treasur north carolina technolog
mr dickinson presid ceo helixi inc director co-found luxtera inc
industri advisori board member mergertech capit manag llc
previous chairman ceo ethentica inc princip bell laboratori
ms grai found inc serv board corvu
pharmaceut inc arca biopharma inc zosano pharma corpor previous
manag member interwest llc attorney wilson sonsini
goodrich rosati pc presid ceo director evp sgx
pharmaceut inc assist clinic professor univers california san
mr young cfo evp serv board cytomx
therapeut inc previous manag director citigroup global market inc
manag director lehman brother inc manag director-glob healthcar barclay
capit inc treasur director inc
mr member kohlberg kravi robert compani kkr lp previous
princip kkr mr serv america health industri team
within privat equiti platform sit strateg growth invest
mr momtaze member head health kkr serv board director
inc accel llc inc previous serv princip
strong histori beat result past quarter beaten consensu
adj ep time beat adj ebtida revenu time
respect like consist adj ebtida adj ep perspect though
believ three straight quarter revenu miss follow straight beat rais slight
caution signal believ may indic manag may becom aggress
growth expect optimist set guidanc
manag recent re-affirmed revenu adj ep guidanc part
earn compani expect revenu suggest
growth guid adj ep step-up
previou year encourag manag expect signific growth bottom
line addit view modest growth top line estim consensu
line manag guidanc adj ep near top guid rang
figur compani guidanc street estim
total revenu grew howev revenu expect
grow much slower rate futur estim growth growth
follow slowdown busi steadi would expect increment
 activ would affect growth rate futur continu expect clinic
research revenu overwhelm major revenu share though
expect growth continu data solut
figur revenu growth expect moder
consensussvb guidanc revenu scienc inc
figur clinic research continu drive revenu
strong adj ebitda growth margin expans
revenu grow compani becom effici expect continu adj ebtida
segment clinic research revenuesdata solut ebitda adj ebitdamargin scienc inc
ep growth seem slow
past two year adj ep grown view
growth favor term manag effort drive bottom line ahead
revenu though expect natur regress ep growth move forward model
growth follow growth
figur adj ep growth expect declin modestli
backlog continu grow
backlog grown consist sinc everi quarter grow least q/q
high q/q backlog stood quarter compani ad
new busi award experienc cancel net new busi
award y/i compar previou four quarter y/i
y/i y/i y/i
figur backlog continu grow
cash total debt ttm basi
gross debt ebitda net debt ebitda view compani debt
level healthi believ room addit leverag compani see
 opportun line expect debt level continu declin
compani pay balanc expect cash balanc grow strong
oper good manag gener view compani rel healthi
move forward expect posit continu improv
seen strong growth cash flow oper past year increas
compani issu lt debt
cover symphoni health acquisit paid lt debt well
acquisit relat conting consider result compani total cf
neg though repay partial off-set strong oper
perform year expect compani continu build cash flow
perform leverag debt balanc enhanc offer posit
market expect tailwind overal cash flow oper
follow recent price run low current level believ
approach fair valu compar comp group differ healthcar cloud/cro compani
includ iclr lh trade
slightli averag price-to-earnings ev/sal basi though rel line
ev/ebitda perspect prah price-to-earnings compar comp group
ev/sal compar comp group ev/ebitda
compar comp group given competit industri current
valuat initi share market perform rate price target
base averag ep ev/sal
fair valu price-to-earnings adj fair valu ev/sal cash share outstand sale price number million except per share datasourc compani file svb leerink llc scienc inc
streetstreet ebitlatesteq epspegmarginshorttickerrat close cloud/crocm river factset market data consensu estim close year calendar applic ebitda ep non-gaap availablenm meaning equiti valu enterpris valu base latest quarter dilut share count equiti valu market cap plu valu stock option treasuri method factset consensu earn estim base factset consensu estimatesp/ ev ebitdaev revenu scienc inc
risk valuat
loss delay non-renew contract would pose threat growth profit
experi routin termin cancel non-renew contract part
ordinari busi client abl termin contract without caus day notic
phase iv tradit project base trial saw cancel
percentag respect mani factor would lead
cancel non-renew includ trial termin financ avail regulatori action
product problem failur drug safeti efficaci standpoint unexpect result
insuffici patient enrol etc due inher cost run trial custom may
decid best bet cancel avoid addit burden cancel rate increas
larger client forc cancel reason may lose prospect growth
opportun current revenu profit potenti would like neg impact
stock
poor fix fee cost estim may result unfavor contract prah
phase iv contract fix fee misinterpret contract poorli estim
inc weekli averag high last inc ev/ebitda ntm high last inc pe ntm high last inc ev/sal ntm scienc inc
relat cost requir fee compani could potenti stuck unprofit contract
extend period time would act headwind profit
extend backlog convers timelin prah backlog convert histor
estim rate compani might come short revenu guidanc consensu estim
could act headwind compani stock price backlog abl
predict rate backlog convert revenu import slowdown would
caus revenu miss acceler may result lower-than-expect backlog
number either occurr could potenti result declin sentiment
percept manag abil accur predict compani backlog convers
result stock price may declin
much prah abil drive growth revolv around attract investig
patient unabl recruit either trial could potenti lose contract hand
may neg impact report revenu growth expect compani abil
attract patient studi becom inferior competitor competit posit
market would like diminish would like hurt valu compani share
deepli root clinic trial market depend continu growth
life scienc market expand strong rate disrupt growth
end market would like neg cro market declin demand clinic
trial demand would soften would like result declin valu
drug price public topic signific decis may neg
affect industri high drug price increasingli public multipl
legisl action process bring cost possibl cap drug price
motion lower price may impact entir industri pharmaceut compani may look
expand portfolio much base lower npv new drug increas
cost develop limit revenu stream post commerci may dissuad
manufactur engag research
multitud patient data breach would like neg impact though
patient data de-identifi breach may decreas investor confid compani
addit secur breach competitor cro data warehous may neg impact
industri whole would headwind
prah revenu rather concentr thirty-six percent revenu
top custom backlog five custom concentr rel high
one custom action may significantli impact prah perform one larg custom
trial fail cancel trial anoth reason could provid larg headwind
prah revenu growth expect
need continu develop technolog remain competit industri
mani larg competitor keep technolog standpoint crucial remain
competit unabl innov new technolog updat exist process
technolog industri advanc could risk lose share competit
would like neg impact share price
incom statement fye decemb
million
revenu
revenu
sell gener administr expens
revenu
depreci amort expens
revenu
loss gain dispos fix asset net
gaap incom oper
loss extinguish debt
incom tax unconcol equiti incom
provis incom tax
incom equiti incom unconsol jv
equiti incom unconsol jv
net incom attribut non-control interest
net incom attribut inc
incom statement fye decemb
million
non- adjust adj ebitda
net incom attribut inc
depreci amort
provis incom tax
loss gain dispos fix asset net
loss extinguish debt
equiti incom unconsolid joint ventur net tax
sever restructur charg
non-oper incom attribut non-controlling interest
non- adjust adj ep
net incom attribut inc
provis incom tax
amort intang asset
amort defer financ cost
amort termin interest rate swap
adjust ebitda
statement flow fye decemb
million
flow oper activ
adjust reconcil net incom net cash provid oper
depreci amort
amort debt issuanc cost
amort termin interest rate swap
chang fair valu acquisit relat conting consider
loss extinguish debt
equiti incom unconsolid jv
chang oper asset liabil
account receiv unbil servic advanc bill
oper asset liabil
payment acquisit relat conting consider
net cash provid use oper activ
flow invest activ
purchas fix asset
proce receiv cash paid interest interet rate swap net
distribut unconsolid joint ventur
net cash provid invest activ
flow financ activ
proce account receiv financ agreement
repay account receiv financ agreement
proce issuanc lt debt
payment acquisition-rel conting consider
repay long term debt
borrow line credit
repay line credit
payment debt repay debt extinguish debt issuanc cost
proce stock issu employe stock purchas plan stock option exercis
net cash use financ activ
effect foreign currenc exchang rate chang cash cash equival restrict cash
chang cash cash equival restrict cash
cash equival restrict cash begin period
cash equival restrict cash end period
balanc sheet fye decemb
million
cash equival
account receiv unbil servic net
liabil redeem non-controlling interest equiti
accru expens current liabil
current portion oper leas liabil
current portion borrow credit facil
current portion long-term debt
long-term portion oper leas liabil
addit paid capit
accumul comprehens loss
equiti attribut inc stockhold
total liabil stockhold equiti
